Phase 3 Clinical Trials With Primary Completion Dates in January 2025
This is a list of Phase 3 trials with primary completion dates in January 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AKESF | Akeso, Inc. | 2025-01-01 | Phase 3 | NCT05587374 | Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
| BHVN | Biohaven Ltd. | 2025-01-01 | Phase 3 | NCT05337553 | A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy |
| IONS | Ionis Pharmaceuticals, Inc. | 2025-01-01 | Phase 3 | NCT05130450 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) |
| NMRA | Neumora Therapeutics, Inc. | 2025-01-01 | Phase 3 | NCT06058013 | Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder |
| ZLAB | Zai Lab Limited | 2025-01-01 | Phase 3 | NCT06162286 | A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP |
| ZLDPF | Zealand Pharma A/S | 2025-01-01 | Phase 3 | NCT03941236 | Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism |